The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Harold J. Burstein

Breast Oncology Center

Dana-Farber Cancer Institute

Harvard Medical School

44 Binney Street

USA

[email]@partners.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, USA. 2010
  • Dana-Farber Cancer Institute, 44 Binney St, Boston, USA. 2002 - 2010
  • Harvard Medical School, Boston, Massachusetts, USA. 2007
  • Division of Medical Oncology and the Department of Medicine, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, USA. 2004

References

  1. Adjuvant hormonal therapy for early-stage breast cancer. Burstein, H.J., Griggs, J.J. Surg. Oncol. Clin. N. Am. (2010) [Pubmed]
  2. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. Burstein, H.J., Sun, Y., Dirix, L.Y., Jiang, Z., Paridaens, R., Tan, A.R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., Abbas, R., Powell, C., Turnbull, K., Vermette, J., Zacharchuk, C., Badwe, R. J. Clin. Oncol. (2010) [Pubmed]
  3. Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age. Burstein, H.J. Breast (2009) [Pubmed]
  4. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Burstein, H.J., Elias, A.D., Rugo, H.S., Cobleigh, M.A., Wolff, A.C., Eisenberg, P.D., Lehman, M., Adams, B.J., Bello, C.L., DePrimo, S.E., Baum, C.M., Miller, K.D. J. Clin. Oncol. (2008) [Pubmed]
  5. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Burstein, H.J., Chen, Y.H., Parker, L.M., Savoie, J., Younger, J., Kuter, I., Ryan, P.D., Garber, J.E., Chen, H., Campos, S.M., Shulman, L.N., Harris, L.N., Gelman, R., Winer, E.P. Clin. Cancer Res. (2008) [Pubmed]
  6. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Burstein, H.J., Storniolo, A.M., Franco, S., Forster, J., Stein, S., Rubin, S., Salazar, V.M., Blackwell, K.L. Ann. Oncol. (2008) [Pubmed]
  7. Aromatase inhibitor-associated arthralgia syndrome. Burstein, H.J. Breast (2007) [Pubmed]
  8. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Burstein, H.J., Keshaviah, A., Baron, A.D., Hart, R.D., Lambert-Falls, R., Marcom, P.K., Gelman, R., Winer, E.P. Cancer (2007) [Pubmed]
  9. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Burstein, H.J., Overmoyer, B., Gelman, R., Silverman, P., Savoie, J., Clarke, K., Dumadag, L., Younger, J., Ivy, P., Winer, E.P. Invest. New. Drugs (2007) [Pubmed]
  10. Anemia in cancer: update on studies of erythropoiesis-stimulating agents. Burstein, H.J. J. Support. Oncol (2007) [Pubmed]
  11. Cognitive side-effects of adjuvant treatments. Burstein, H.J. Breast (2007) [Pubmed]
  12. Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer. Burstein, H.J. Oncology (Williston Park, N.Y.) (2006) [Pubmed]
  13. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Burstein, H.J., Bellon, J.R., Galper, S., Lu, H.M., Kuter, I., Taghian, A.G., Wong, J., Gelman, R., Bunnell, C.A., Parker, L.M., Garber, J.E., Winer, E.P., Harris, J.R., Powell, S.N. Int. J. Radiat. Oncol. Biol. Phys. (2006) [Pubmed]
  14. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Burstein, H.J., Mayer, E., Patridge, A.H., O'Kane, H., Litsas, G., Come, S.E., Hudis, C.A., Goldstein, D.F., Muss, H.B., Winter, E.P., Garber, J.E. Clin. Breast Cancer (2006) [Pubmed]
  15. Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA. Burstein, H.J. Expert. Rev. Anticancer. Ther (2005) [Pubmed]
  16. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Burstein, H.J., Lieberman, G., Slamon, D.J., Winer, E.P., Klein, P. Ann. Oncol. (2005) [Pubmed]
  17. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. Burstein, H.J., Parker, L.M., Keshaviah, A., Doherty, J., Partridge, A.H., Schapira, L., Ryan, P.D., Younger, J., Harris, L.N., Moy, B., Come, S.E., Schumer, S.T., Bunnell, C.A., Haldoupis, M., Gelman, R., Winer, E.P. J. Clin. Oncol. (2005) [Pubmed]
  18. Ductal carcinoma in situ of the breast. Burstein, H.J., Polyak, K., Wong, J.S., Lester, S.C., Kaelin, C.M. N. Engl. J. Med. (2004) [Pubmed]
  19. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Burstein, H.J., Demetri, G.D., Mueller, E., Sarraf, P., Spiegelman, B.M., Winer, E.P. Breast Cancer Res. Treat. (2003) [Pubmed]
  20. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Burstein, H.J., Harris, L.N., Marcom, P.K., Lambert-Falls, R., Havlin, K., Overmoyer, B., Friedlander, R.J., Gargiulo, J., Strenger, R., Vogel, C.L., Ryan, P.D., Ellis, M.J., Nunes, R.A., Bunnell, C.A., Campos, S.M., Hallor, M., Gelman, R., Winer, E.P. J. Clin. Oncol. (2003) [Pubmed]
  21. Treatment of breast cancer during pregnancy. Burstein, H.J., Partridge, A.H., Lesnikoski, B.A. Expert. Opin. Pharmacother (2002) [Pubmed]
 
WikiGenes - Universities